Nasus Pharma Ltd
NSRX- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0002029039
No open-market purchases or sales by Nasus Pharma Ltd insiders were filed in the last 90 days; 10 institutions reported holding it in 13F filings for Q2 2026, worth $7.53M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Nasus Pharma Ltd insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Nasus Pharma Ltd, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Rubin Eyal | Chief Financial Officer | – | Sep 21, 2026 | 1 |
| Teleman Dan Benjamin | Chief Executive Officer | 163,541 | Jul 29, 2026 | 4 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jun 22, 2026 (view filing) | Jun 17 | 5 days | Teleman Dan BenjaminChief Executive Officer | PPurchase | +6.55K | $3.10 | +$20.3K | +4.2%163.5K after | |
| Apr 22, 2026 (view filing) | Apr 22 | Same day | Teleman Dan BenjaminChief Executive Officer | PPurchase | +2.90K | $3.76 | +$10.9K | +1.9%157.0K after | |
| Apr 1, 2026 (view filing) | Mar 31 | 1 day | Teleman Dan BenjaminChief Executive Officer | PPurchase | +15.0K | $2.04 | +$30.6K | +240.2%21.2K after |